APRINOIA Therapeutics, a Phase 3 biotech developing diagnostics and therapies for neurodegenerative diseases, withdrew its plans for an initial public offering on Monday. It originally filed in January 2024 and most recently planned to raise $6 million by...read more
APRINOIA Therapeutics, a Phase 3 biotech developing diagnostics and therapies for neurodegenerative diseases, lowered the proposed deal size for its upcoming IPO on Wednesday. The Cambridge, MA-based company now plans to raise $6 million by offering 0.5 million...read more
APRINOIA Therapeutics, a Phase 3 biotech developing diagnostics and therapies for neurodegenerative diseases, lowered the proposed deal size for its upcoming IPO on Wednesday. The Cambridge, MA-based company now plans to raise $6 million by offering 0.5 million...read more
APRINOIA Therapeutics, a Phase 3 biotech developing diagnostics and therapies for neurodegenerative diseases, announced terms for its IPO on Monday. The Cambridge, MA-based company plans to raise $24 million by offering 2 million shares at a price range of $10...read more
Neurodegenerative disease biotech APRINOIA Therapeutics withdraws $6 million IPO
APRINOIA Therapeutics, a Phase 3 biotech developing diagnostics and therapies for neurodegenerative diseases, withdrew its plans for an initial public offering on Monday. It originally filed in January 2024 and most recently planned to raise $6 million by...read more
Neurodegenerative disease biotech APRINOIA Therapeutics narrows range ahead of $6 million IPO
APRINOIA Therapeutics, a Phase 3 biotech developing diagnostics and therapies for neurodegenerative diseases, lowered the proposed deal size for its upcoming IPO on Wednesday. The Cambridge, MA-based company now plans to raise $6 million by offering 0.5 million...read more
Neurodegenerative disease biotech APRINOIA Therapeutics slashes share offering by 75% ahead of $6 million IPO
APRINOIA Therapeutics, a Phase 3 biotech developing diagnostics and therapies for neurodegenerative diseases, lowered the proposed deal size for its upcoming IPO on Wednesday. The Cambridge, MA-based company now plans to raise $6 million by offering 0.5 million...read more
Neurodegenerative disease biotech APRINOIA Therapeutics sets terms for $24 million IPO
APRINOIA Therapeutics, a Phase 3 biotech developing diagnostics and therapies for neurodegenerative diseases, announced terms for its IPO on Monday. The Cambridge, MA-based company plans to raise $24 million by offering 2 million shares at a price range of $10...read more